The Utility of Multitarget Stool DNA Testing for Colorectal Cancer Screening After a Normal Colonoscopy.
Cologuard®
Colon cancer
Colon cancer screening
Colonoscopy
Fecal immunochemical test
Multitarget stool DNA tests
Journal
Journal of gastrointestinal cancer
ISSN: 1941-6636
Titre abrégé: J Gastrointest Cancer
Pays: United States
ID NLM: 101479627
Informations de publication
Date de publication:
17 Oct 2024
17 Oct 2024
Historique:
accepted:
07
10
2024
medline:
17
10
2024
pubmed:
17
10
2024
entrez:
16
10
2024
Statut:
epublish
Résumé
Multitarget stool DNA (MT-sDNA) tests (here, Cologuard®) are currently used in average-risk patients as a primary method of screening for colorectal cancer. However, MT-sDNA testing has also been used in patients who previously underwent colonoscopy who wish to avoid repeat colonoscopy. Here, in a large primary care practice setting, our aim was to evaluate the diagnostic performance of MT-sDNA testing in patients with a previously normal colonoscopy. This retrospective cohort study included 5827 patients from 35 different primary locations in South Carolina. Patients aged 45 and above with a previously documented normal, high-quality colonoscopy prior to the MT-sDNA test date were included. High-risk patients and those with a previous negative MT-sDNA result were excluded. Of 5827 ordered MT-sDNA tests, 248 patients had a prior normal colonoscopy. The average time from initial colonoscopy to MT-sDNA testing was 7.3 years. Of the 63 patients who had a positive MT-sDNA test, 41 patients (65%) completed follow-up colonoscopy and 40 patients had complete colonoscopy data. Of these 40 patients, 12 patients (30%) had advanced adenomas and none had colorectal cancer. Compared to patients without a previous colonoscopy, patients with prior colonoscopies had fewer adenomas of all types (1.6 vs 2.4) and fewer advanced adenomas (1.4 vs 2.0). Patients with a previously negative colonoscopy and subsequent positive MT-sDNA test were found to have a high rate of advanced adenomas on follow-up colonoscopy (30%). Thus, in patients with a previously negative colonoscopy, MT-sDNA testing may be a reasonable alternative screening option.
Sections du résumé
BACKGROUND
BACKGROUND
Multitarget stool DNA (MT-sDNA) tests (here, Cologuard®) are currently used in average-risk patients as a primary method of screening for colorectal cancer. However, MT-sDNA testing has also been used in patients who previously underwent colonoscopy who wish to avoid repeat colonoscopy. Here, in a large primary care practice setting, our aim was to evaluate the diagnostic performance of MT-sDNA testing in patients with a previously normal colonoscopy.
METHODS
METHODS
This retrospective cohort study included 5827 patients from 35 different primary locations in South Carolina. Patients aged 45 and above with a previously documented normal, high-quality colonoscopy prior to the MT-sDNA test date were included. High-risk patients and those with a previous negative MT-sDNA result were excluded.
RESULTS
RESULTS
Of 5827 ordered MT-sDNA tests, 248 patients had a prior normal colonoscopy. The average time from initial colonoscopy to MT-sDNA testing was 7.3 years. Of the 63 patients who had a positive MT-sDNA test, 41 patients (65%) completed follow-up colonoscopy and 40 patients had complete colonoscopy data. Of these 40 patients, 12 patients (30%) had advanced adenomas and none had colorectal cancer. Compared to patients without a previous colonoscopy, patients with prior colonoscopies had fewer adenomas of all types (1.6 vs 2.4) and fewer advanced adenomas (1.4 vs 2.0).
CONCLUSION
CONCLUSIONS
Patients with a previously negative colonoscopy and subsequent positive MT-sDNA test were found to have a high rate of advanced adenomas on follow-up colonoscopy (30%). Thus, in patients with a previously negative colonoscopy, MT-sDNA testing may be a reasonable alternative screening option.
Identifiants
pubmed: 39414672
doi: 10.1007/s12029-024-01118-3
pii: 10.1007/s12029-024-01118-3
doi:
Substances chimiques
DNA, Neoplasm
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Imperiale TF, Porter K, Zella J, Gagrat ZD, Olson MC, Statz S, et al. Next-generation multitarget stool DNA test for colorectal cancer screening. N Engl J Med. 2024;390(14):984–993.
Anand S, Liang PS. A practical overview of the stool DNA test for colorectal cancer screening. Clin Transl Gastroenterol. 2022;13(4):e00464.
doi: 10.14309/ctg.0000000000000464
pmcid: 9038502
Eckmann JD, Ebner DW, Bering J, Kahn A, Rodriguez E, Devens ME, et al. Multitarget stool DNA screening in clinical practice: high positive predictive value for colorectal neoplasia regardless of exposure to previous colonoscopy. Am J Gastroenterol. 2020;115(4):608–15.
doi: 10.14309/ajg.0000000000000546
pmcid: 7127971
Voss JK, Ebner DW, Burger KN, Mahoney DW, Devens ME, Lowrie KL, et al. Multitarget stool DNA testing has high positive predictive value for colorectal neoplasia on the second round of testing. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2023;21(9):2399–406.
Dhaliwal A, Vlachostergios PJ, Oikonomou KG, Moshenyat Y. Fecal DNA testing for colorectal cancer screening: molecular targets and perspectives. World J Gastrointest Oncol. 2015;7(10):178–83.
doi: 10.4251/wjgo.v7.i10.178
pmcid: 4606173
Wolf AMD, Fontham ETH, Church TR, Flowers CR, Guerra CE, LaMonte SJ, et al. Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society. CA Cancer J Clin. 2018;68(4):250–81.
doi: 10.3322/caac.21457
Siegel RL, Wagle NS, Cercek A, Smith RA, Jemal A. Colorectal cancer statistics, 2023. CA Cancer J Clin. 2023;73(3):233–54.
doi: 10.3322/caac.21772
pubmed: 36856579
Cooper GS, Markowitz SD, Chen Z, Tuck M, Willis JE, Berger BM, et al. Evaluation of patients with an apparent false positive stool DNA test: the role of repeat stool DNA testing. Dig Dis Sci. 2018;63(6):1449–53.
doi: 10.1007/s10620-018-5001-z
pmcid: 5960589
Heisser T, Guo F, Niedermaier T, Holleczek B, Hoffmeister M, Brenner H. Low risk of advanced neoplasms for up to 20 years after negative colonoscopy result: potential for personalized follow-up screening intervals. Gastroenterology. 2020;159(6):2235-2237.e4.
doi: 10.1053/j.gastro.2020.08.003
Lieberman DA, et al. Use of colonoscopy to screen asymptomatic adults for colorectal cancer. Veterans Affairs Cooperative Study Group 380. N Engl J Med. 2000;343(3):162–8.
doi: 10.1056/NEJM200007203430301
Forbes N, Hilsden RJ, Martel M, Ruan Y, Dube C, Rostom A, et al. Association between time to colonoscopy after positive fecal testing and colorectal cancer outcomes: a systematic review. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2021;19(7):1344-1354.e8.
Corley DA, Jensen CD, Quinn VP, Doubeni CA, Zauber AG, Lee JK, et al. Association between time to colonoscopy after a positive fecal test result and risk of colorectal cancer and cancer stage at diagnosis. JAMA. 2017;317(16):1631–41.
doi: 10.1001/jama.2017.3634
pmcid: 6343838
Patel K, VanLeer-Greenberg B. Artificial intelligence in colonoscopy in a community setting. Am J Gastroenterol. 2023;118(Suppl 1). Available from: https://journals.lww.com/ajg/fulltext/2023/10001/s353_artificial_intelligence_in_colonoscopy_in_the.709.aspx .
Ishtiaq R, Zulfiqar L, Gangwani MK, Aziz M. Adenoma detection rate vs. adenoma per colonoscopy as quality indicators for colon cancer screening. Transl Gastroenterol Hepatol. 2023;8:24.
doi: 10.21037/tgh-22-92
pmcid: 10432231
Kim NH, Jung YS, Jeong WS, Yang HJ, Park SK, Choi K, et al. Miss rate of colorectal neoplastic polyps and risk factors for missed polyps in consecutive colonoscopies. Intest Res. 2017;15(3):411–8.
doi: 10.5217/ir.2017.15.3.411
pmcid: 5478767
Ezaz G, Leffler DA, Beach S, Schoen RE, Crockett SD, Gourevitch RA, et al. Association between endoscopist personality and rate of adenoma detection. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2019;17(8):1571-1579.e7.